Acorda Therapeutics Inc ACOR:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:22 PM EST
5.91quote price arrow up+0.09 (+1.55%)
Volume
1,155
Close
5.82quote price arrow down-0.23 (-3.80%)
Volume
146,349
52 week range
2.53 - 9.84

...

Loading . . .

KEY STATS

  • Open6.05
  • Day High6.07
  • Day Low5.65
  • Prev Close6.05
  • 52 Week High9.84
  • 52 Week High Date10/20/20
  • 52 Week Low2.53
  • 52 Week Low Date09/14/20
  • Market Cap55.17M
  • Shares Out9.48M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta0.56
  • 1 Year % Change-26.52

RATIOS/PROFITABILITY

  • EPS (TTM)5.32
  • P/E (TTM)1.09
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)59.73M
  • ROE (MRQ)16.51%
  • Revenue (MRQ)165.30M
  • Gross Margin (MRQ)81.04%
  • Net Margin (MRQ)29.71%
  • Debt To Equity (MRQ)73.25%

EVENTS

  • Earnings Date05/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Acorda Therapeutics Inc News

There is no recent news for this security.

Latest ACOR News From Our Partners

February 19, 2021

QUOTE FINDER

Profile

MORE
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also...
John Kelley
Non-Executive Chairman
Ron Cohen M.D.
Chief Executive Officer
David Lawrence
Chief Accounting Officer
Address
420 Saw Mill River Rd
Ardsley, NY
10502-2605
United States